Bovine Leukemia Virus: Welfare in Affected Dairy Herds

Key Facts

• BLV infects B lymphocytes — up to 40% of US dairy cows test positive for BLV antibodies
• Only 1-5% of infected cattle develop clinical lymphosarcoma, but this represents many thousands of animals globally
• Clinical lymphosarcoma causes weight loss, lymph node enlargement, heart failure, or neurological signs depending on tumor location
• There is no treatment for bovine lymphosarcoma — welfare management focuses on comfort until euthanasia
• Control relies on testing and removal of positive animals in eradication programs, or hygiene measures to reduce spread

Welfare Considerations

BLV creates a welfare challenge where the majority of infected animals live normal lives, but a minority develop progressive, untreatable cancer. Lymphosarcoma causes suffering that varies with tumor location: cardiac tumors cause congestive heart failure, abomasal tumors cause weight loss and anemia, and spinal cord tumors cause paralysis. The welfare imperative for animals developing clinical disease is early recognition and prompt euthanasia when quality of life deteriorates — not prolonged treatment. Eradication programs that test and remove BLV-positive animals reduce the pool of infected cattle but have significant economic and management implications.

What You Can Do

• Monitor BLV-positive cattle for early signs of lymphosarcoma: unexplained weight loss, lymph node enlargement, cardiac signs
• Implement hygiene measures to reduce BLV spread: single-use needles, clean dehorning instruments, gloves for rectal examination
• Euthanize cattle with clinical lymphosarcoma when quality of life declines — there is no welfare-justified curative treatment
• Consider a BLV eradication program to reduce herd prevalence and long-term disease incidence
• Inform milk buyers and certification bodies of BLV status as part of transparent herd health management